Current Status and Prospects of Immunotherapy for Osteosarcoma

VernacularTitle:骨肉瘤免疫治疗的现状和前景
Author: Wei WU ¹ ; Doudou JING ; Li CAO ; Feifei PU ; Zengwu SHAO
Author Information

1. Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Publication Type:Research Article
Keywords: Osteosarcoma; Tumor immune escape; Immunotherapy
From: Cancer Research on Prevention and Treatment 2022;49(7):721-726
CountryChina
Language:Chinese
Abstract: Osteosarcoma is a malignant tumor with extreme invasiveness and metastasis as well as dismal prognosis. It is critical to rapidly find a unique therapy strategy capable of significantly improving the prognosis of osteosarcoma. Tumor immunotherapy has the potential to reawaken the immune system, restart and sustain the tumor-immune cycle in the body, resulting in the death of tumor cells. CD8+ CTL, CD4+ T cells, NK cells and NKT cells all play critical roles in tumor immunity, while humoral immunity may not only inhibit tumor growth but also enhance it. Researchers have devised various strategies to boost the immune system in recent years based on tumor immune response studies. This paper highlights and examines osteosarcoma immunotherapy from two perspectives: (1) boosting the response of patient's own immune system to the tumor; (2) exogenously improving the patient's immunological function.